β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer

Programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) checkpoint blocking antibodies have been shown to be a powerful immune checkpoint blockade (ICB) therapy for patients with cancer. However, patients quickly develop resistance to immunotherapy. β-glucan, an immune adjuvant, has been found to stimulate in...

Full description

Bibliographic Details
Published in:	Frontiers in Pharmacology
Main Authors:	Mengjie Wang, Yu Bai, Jiaxin Pei, Dongqing Li, Xiaolin Pu, Wenyu Zhu, Lei Xia, Chunjian Qi, Hua Jiang, Yongling Ning
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-04-01
Subjects:	β-Glucan PD-1 PD-L1 immune checkpoint blockade therapy resistance
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.887457/full

Similar Items

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
by: Zijun Y. Xu-Monette, et al.
Published: (2017-12-01)

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
by: Menglei Jin, et al.
Published: (2024-11-01)

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
by: Jin-Yu Sun, et al.
Published: (2020-08-01)

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
by: Jan Willem Kleinovink, et al.
Published: (2017-04-01)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
by: Weijie Ma, et al.
Published: (2016-05-01)

Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
by: Yiting Sun, et al.
Published: (2021-08-01)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
by: Dongxu Wang, et al.
Published: (2019-04-01)

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
by: Rui Zhao, et al.
Published: (2021-01-01)

PD-L1 immune suppression in cancer: Tumor cells or host cells?
by: Jan Willem Kleinovink, et al.
Published: (2017-07-01)

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
by: Dylan J. Martini, et al.
Published: (2017-08-01)

A novel nanomedicine integrating ferroptosis and photothermal therapy, well-suitable for PD-L1-mediated immune checkpoint blockade
by: Yujun Bao, et al.
Published: (2024-12-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy
by: Vishnu Vijay Vijayan, et al.
Published: (2024-12-01)

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
by: Shuguang Tan, et al.
Published: (2016-11-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

Peptide Blockers of PD-1-PD-L1 Interaction Reinvigorate PD-1-Suppressed T Cells and Curb Tumor Growth in Mice
by: Shanshan (Jenny) Zhong, et al.
Published: (2024-07-01)

N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1
by: Bar Kaufman, et al.
Published: (2025-05-01)

Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancer
by: Qi Xie, et al.
Published: (2024-11-01)

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy
by: Shengzhe Jin, et al.
Published: (2024-03-01)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
by: Tingxuan Gu, et al.
Published: (2023-05-01)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
by: William L. Redmond, et al.
Published: (2023-02-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical Setting
by: Damianos-Ioannis Zervanos, et al.
Published: (2025-08-01)

Elucidating the role of N-myristoylation in the excessive membrane localization of PD-L1 in hypoxic cancers and developing a novel NMT1 inhibitor for combination with immune checkpoint blockade therapy
by: Haoming Zhao, et al.
Published: (2025-07-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
by: Ruiting Li, et al.
Published: (2021-06-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021-02-01)

Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin
by: Shaomeng Chen, et al.
Published: (2021-09-01)

Exosomal PD-L1 detection in cancer predictive biomarker for response to immune checkpoint blockade therapy
by: Tetsuichi Kansha, et al.
Published: (2025-07-01)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
by: Qian Li, et al.
Published: (2022-12-01)

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
by: Xintong Li, et al.
Published: (2024-11-01)

Editorial: Natural products modulate the sensitivity of cancer to anti-PD-1 based immunotherapy
by: Jean Christopher Chamcheu, et al.
Published: (2023-06-01)

Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
by: Zachary S. Buchwald, et al.
Published: (2018-12-01)

PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma
by: Joshua W. D. Tobin, et al.
Published: (2021-05-01)

Cancer therapeutic implications of microRNAs in the regulation of immune checkpoint blockade
by: Yan Zhang, et al.
Published: (2019-08-01)

Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
by: Sadique A. Javed, et al.
Published: (2024-04-01)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
by: Long Jia, et al.
Published: (2018-06-01)

Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy
by: Junghwa Lee, et al.
Published: (2023-07-01)

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
by: Yanna Lei, et al.
Published: (2021-03-01)

Efficacy and safety of immune checkpoint blockade for brain metastases
by: Maya Harary, et al.
Published: (2019-06-01)

Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
by: Huilin Ou, et al.
Published: (2022-08-01)